文献速递MDS 与骨髓增殖性肿瘤白血病

PD-L1过表达与骨髓增殖性肿瘤中JAK2-V617F突变负荷相关并与9p单亲二体相关

PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.
PubMed 文献 · Am J Hematol · 2022-01-21

对113例骨髓增殖性肿瘤患者粒细胞行RNA测序,发现PD-L1表达在真性红细胞增多症患者中最高,且与JAK2-V617F突变负荷相关(R=0.52;p<.0001)。SNP阵列显示9p单亲二体覆盖PD-L1和JAK2,携带9p单亲二体者PD-L1表达更高(p<.0001)。PD-L1在CD34+CD38-疾病起始干细胞高表达,暴露于JAK2抑制剂和BRD4靶向药物后过表达降低。

要点

  • PD-L1表达在真性红细胞增多症患者中最高,且与JAK2-V617F突变负荷相关(R=0.52;p<.0001)。
  • 9p单亲二体覆盖PD-L1和JAK2,JAK2-V617F阳性患者中伴9p单亲二体者PD-L1表达更高(p<.0001)。
  • PD-L1在JAK2和CALR突变患者的CD34+CD38-疾病起始干细胞高表达,JAK2抑制剂和BRD4靶向药物可降低其过表达。

核心结论

  • PD-L1过表达与JAK2-V617F突变负荷相关,并与9p单亲二体相关;PD-L1在疾病起始干细胞高表达,暴露于JAK2抑制剂和BRD4靶向药物后降低。
  • 靶向PD-L1能否克服骨髓增殖性肿瘤中疾病起始干细胞的耐药尚待 forthcoming 研究阐明。

研究设计与样本

  • 对113例骨髓增殖性肿瘤患者粒细胞行RNA测序。
  • 采用单核苷酸多态性(SNP)阵列检测9p单亲二体。
  • 进行单倍型关联分析以评估PD-L1位点胚系遗传因素。

主要发现

  • PD-L1表达在真性红细胞增多症患者中最高。
  • PD-L1表达与JAK2-V617F突变负荷相关(R=0.52;p<.0001)。
  • SNP阵列显示9p单亲二体覆盖PD-L1和JAK2在所有受检骨髓增殖性肿瘤患者中。
  • JAK2-V617F阳性患者中,伴9p单亲二体者PD-L1表达高于不伴者(p<.0001)。
  • PD-L1在JAK2和CALR突变骨髓增殖性肿瘤的CD34+CD38-疾病起始干细胞高表达。

关键数值与推荐

  • JAK2体细胞突变驱动50-60%病例,CALR突变驱动25-30%病例。
  • PD-L1表达与JAK2-V617F突变负荷相关(R=0.52;p<.0001)。
  • JAK2-V617F阳性患者中,伴9p单亲二体者PD-L1表达高于不伴者(p<.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 靶向PD-L1能否克服骨髓增殖性肿瘤中疾病起始干细胞的耐药尚待 forthcoming 研究阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative neoplasms (MPN) are chronic stem cell disorders characterized by enhanced proliferation of myeloid cells, immune deregulation, and drug resistance. JAK2 somatic mutations drive the disease in 50-60% and CALR mutations in 25-30% of cases. Published data suggest that JAK2-V617F-mutated MPN cells express the resistance-related checkpoint PD-L1. By applying RNA-sequencing on granulocytes of 113 MPN patients, we demonstrate that PD-L1 expression is highest among polycythemia vera patients and that PD-L1 expression correlates with JAK2-V617F mutational burden (R = 0.52; p < .0001). Single nucleotide polymorphism (SNP) arrays showed that chromosome 9p uniparental disomy (UPD) covers both PD-L1 and JAK2 in all MPN patients examined. MPN cells in JAK2-V617F-positive patients expressed higher levels of PD-L1 if 9p UPD was present compared to when it was absent (p < .0001). Moreover, haplotype-based association analyses provided evidence for germline genetic factors at PD-L1 locus contributing to MPN susceptibility independently of the previously described GGCC risk haplotype. We also found that PD-L1 is highly expressed on putative CD34+ CD38- disease-initiating neoplastic stem cells (NSC) in both JAK2 and CALR-mutated MPN. PD-L1 overexpression decreased upon exposure to JAK2 blockers and BRD4-targeting agents, suggesting a role for JAK2-STAT5-signaling and BRD4 in PD-L1 expression. Whether targeting of PD-L1 can overcome NSC resistance in MPN remains to be elucidated in forthcoming studies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Milosevic Feenstra JD, Jäger R, Schischlik F, et al. PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. Am J Hematol. 2022. PMID: 35015307. doi:10.1002/ajh.26461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。